For the first time in the United States, parents can walk into a store and purchase a continuous glucose monitoring device for a child as young as two years old — no doctor’s visit, no prescription required. The US Food and Drug Administration announced on June 13, 2026 that it has granted marketing clearance to Dexcom Inc.’s Stelo Glucose Biosensor System for children and individuals aged two and older who do not rely on insulin to manage blood sugar.
The decision marks a significant expansion of a product the FDA originally authorized in March 2024 solely for adults 18 years of age and older. At that time, Stelo became the first over-the-counter (OTC) continuous glucose monitor (CGM) ever cleared for use in the United States — a milestone that reshaped the consumer health technology landscape. The latest pediatric clearance builds on that foundation, formally extending the OTC CGM market to children for the very first time.
Who the Device Is Intended For
According to the FDA, the Stelo clearance for pediatric users covers two broad groups: children diagnosed with diabetes who manage the condition through oral medication rather than insulin, and children without any diabetes diagnosis whose families wish to track how diet, physical activity, and other lifestyle habits influence glucose levels. The device is explicitly not authorized for individuals who use insulin — whether children or adults — due to the specific nature of how it monitors and displays data.
The agency also emphasized that the Stelo system is not designed for people with problematic hypoglycemia, meaning dangerously low blood sugar episodes, as the device does not generate alerts for that condition. It is likewise not indicated for individuals undergoing dialysis. The FDA further noted that anyone with a history of disordered eating should consult a healthcare provider before using the device.
FDA Official Points to Pediatric Health Innovation
Dr. Michelle Tarver, director of the FDA’s Center for Devices and Radiological Health, issued a formal statement underscoring the agency’s commitment to expanding health management tools for younger patients. Dr. Tarver stated that children deserve access to the best available tools for managing their health, and described the clearance as a reflection of the FDA’s dedication to “fostering innovation for pediatric patients and supporting the safe and effective use of medical devices where children live, learn, and play.”
The FDA framed the decision as part of a wider regulatory effort to bring consumer-grade health monitoring to populations that have historically been underserved by over-the-counter medical devices — particularly children, who have long been excluded from the non-prescription health technology market.
Rising Prediabetes Rates in Children Drove the Regulatory Push
A key public health concern underpinning the clearance is the growing prediabetes crisis among American children. The FDA, in its announcement, cited rising rates of prediabetes among young people in the United States as a direct driver of the decision. Millions of children are now considered at heightened risk of progressing to Type 2 diabetes — a trajectory that early glucose awareness may help interrupt.
The agency said that real-time glucose data delivered by devices like Stelo could help children and their caregivers develop what it called “glycemic awareness” — a practical understanding of how the body responds to meals, physical movement, and other everyday behaviors. The FDA said this kind of early awareness could support healthier long-term health outcomes for young users.
How the Stelo System Works
The Stelo Glucose Biosensor System uses a small wearable sensor placed directly on the skin. The sensor reads glucose levels from interstitial fluid located just beneath the skin’s surface — eliminating the need for traditional finger-prick blood draws. It pairs with a compatible smartphone application that continuously measures, records, analyzes, and displays glucose values and trend data.
The accompanying app can be installed on a parent’s or caregiver’s smartphone, enabling remote monitoring of a child’s glucose trends throughout the day and night. Readings are refreshed every 15 minutes, offering a near-continuous picture of blood sugar fluctuations. Each sensor is rated to last up to 15 days before replacement is needed, though the FDA noted that actual wear time in children may be shorter than in adults due to physiological and behavioral differences unique to pediatric users.
The FDA stressed that Stelo readings should be used as a supplementary health tool in coordination with a licensed healthcare provider — not as a standalone basis for making medication or treatment decisions. For pediatric users specifically, the device must be used under the active supervision of an adult caregiver at all times.
Real-World and Clinical Data Supported the Pediatric Authorization
The FDA’s decision to extend Stelo’s clearance to children was supported by a combination of data streams, according to the agency’s announcement. Dexcom and the FDA together evaluated earlier clinical study data drawn from both pediatric and adult populations, alongside real-world data reflecting integrated CGM use across both age groups. This combined dataset was used to assess how the device would perform across the full 15-day wear cycle in pediatric users.
The FDA said the integration of real-world evidence alongside prospective clinical trial data was deemed sufficient to demonstrate the device’s safety and effectiveness profile for the intended pediatric population. This blended methodology increasingly reflects how the FDA approaches device authorizations — particularly in cases where large-scale pediatric clinical trials present logistical or ethical difficulties.
Reported Side Effects and Safety Cautions
Clinical study participants reported mild adverse events associated with sensor use, including skin irritation, localized infection, and pain or discomfort at the site where the sensor was applied, according to the FDA. These findings were disclosed as part of the clearance documentation.
The agency was unambiguous in its guidance: Stelo is a supplementary monitoring tool. Any adjustments to a child’s medication regimen or treatment plan based on data from the device should only be made in consultation with a qualified healthcare professional.
Dexcom Expands a Market It Helped Create
Dexcom’s original March 2024 clearance for adult OTC CGM use was widely recognized as a landmark moment in consumer health technology. It opened non-prescription glucose monitoring to a far broader population than had previously had access — particularly individuals managing prediabetes or general wellness goals outside a formal clinical framework. The technology drew attention from both the healthcare sector and consumer wellness industry, prompting other manufacturers to develop competing products in the growing OTC CGM space.
Dexcom has previously said that the Stelo platform was purpose-built for non-insulin users, featuring a 15-day sensor lifespan and a cash-pay pricing model that allows consumers to purchase the device without a prescription drug benefit plan.
Aligned With FDA’s Home Health Initiative
The FDA said the pediatric clearance is consistent with its Home as a Health Care Hub Initiative — a regulatory program designed to advance patient-centered medical devices that integrate more naturally into everyday life outside of clinical environments. The initiative reflects a broader policy direction at the agency toward enabling health monitoring and management to occur increasingly in home settings, reducing dependence on in-clinic testing for conditions that wearable or consumer-grade technology can reliably track.
With the June 13, 2026 clearance now in effect, the over-the-counter continuous glucose monitor market formally encompasses children as young as two years old. The FDA described the development as meeting families where they are — while maintaining its position that data from the Stelo device should always be interpreted in partnership with licensed medical professionals rather than used to independently guide health decisions.
Originally reported by: MedPage Today / HealthDay / FDA announcement (wire reports)
